ArticleJournal of infection and public health2023
Designing multi-epitope monkeypox virus-specific vaccine using immunoinformatics approach.
Article in Journal of infection and public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 53 citations in OpenAlex.
- Design and Evaluation of a Multi-Epitope Vaccine Targeting Conserved Envelope and NS5 Proteins of Usutu Virus Using Immunoinformatics.Microorganisms · 2026Article
- Immunoinformatic Design and Evaluation of a Multi-Epitope mRNA Vaccine RP14914P Targeting Latent Tuberculosis Infection.Pathogens (Basel, Switzerland) · 2026Article
- Article
- In silico design and immunoinformatics assessment of a multiepitope vaccine targeting borealpox virus.Scientific reports · 2026Article
- Severe viral rash progression prediction and surveillance early warning based on local-global attention and temporal convolutional network.Frontiers in public health · 2026Article
- Designing of Peptide Vaccine by Investigating Monkeypox Virus Membrane Glycoprotein: An IntegratedCurrent medicinal chemistry · 2026Article
- Immunoinformatic based designing of highly immunogenic multi-epitope subunit vaccines to stimulate an adaptive immune response against Junin virus.Molecular diversity · 2025Article
- Identification of potential antigenic proteins and epitopes for the development of a monkeypox virus vaccine: an in silico approach.Molecular diversity · 2025Article
- A robust comprehensive immunoinformatics approach for designing a potential multi-epitope based vaccine against a reiterated monkeypox virus.Biochemistry and biophysics reports · 2025Article
- Design of a multi-Epitope mRNA vaccine against Brucella type IV secretion system using reverse vaccinology and immunogenicity approaches.Scientific reports · 2025Article
- Multi-epitope vaccines: charting a new frontier in monkeypox prevention and control.Human cell · 2025Review
- Design of a novel multiepitope vaccine against glioblastoma by in silico approaches.Scientific reports · 2025Article
- Article
- Design of multi-epitope chimeric vaccine against Monkeypox virus and SARS-CoV-2: A vaccinomics perspective.Journal of cellular and molecular medicine · 2024Article
- Article
- Immunomodulatory Peptides as Vaccine Adjuvants and Antimicrobial Agents.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Acyl pyrazole sulfonamides as new antidiabetic agents: synthesis, glucosidase inhibition studies, and molecular docking analysis.Frontiers in chemistry · 2024Article
- In silico analysis of virulence factors ofIn silico pharmacology · 2024Article
- Multi-epitope vaccine design using in silico analysis of glycoprotein and nucleocapsid of NIPAH virus.PloS one · 2024Article
- Computer-Aided Multi-Epitope Based Vaccine Design Against Monkeypox Virus Surface Protein A30L: An Immunoinformatics Approach.The protein journal · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMonkeypox virus is an enveloped DNA virus that belongs to Poxviridae family. The virus is transmitted from rodents to primates via infected body fluids, skin lesions, and respiratory droplets. After being infected with virus, the patients experience fever, myalgia, maculopapular rash, and fluid-filled blisters. It is necessary to differentiate monkeypox virus from other poxviruses during diagnosis which can be appropriately envisioned via DNA analysis from swab samples. During small outbreaks, the virus is treated with therapies administered in other orthopoxviruses infections and does not have its own specific therapy and vaccine. Consequently, in this article, two potential peptides have been designed.
methodsFor the purpose of designing a vaccine, protein sequences were retrieved followed by the prediction of B- and T-cell epitopes. Afterward, vaccine structures were predicted which were docked with toll-like receptors. The docked complexes were analyzed with iMODS. Moreover, vaccine constructs nucleotide sequences were optimized and expressed in silico.
resultsCOP-B7R vaccine construct (V1) has antigenicity score of 0.5400, instability index of 29.33, z-score of - 2.11-, and 42.11% GC content whereas COP-A44L vaccine construct (V2) has an antigenicity score of 0.7784, instability index of 23.33, z-score of - 0.61, and 48.63% GC content. It was also observed that COP-A44L can be expressed as a soluble protein in Escherichia coli as compared to COP-B7R which requires a different expression system.
conclusionThe obtained results revealed that both vaccine constructs show satisfactory outcomes after in silico investigation and have significant potential to prevent the monkeypox virus. However, COP-A44L gave better results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.